Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 4
2005 3
2006 4
2007 2
2008 3
2009 14
2010 2
2011 4
2012 6
2013 11
2014 6
2015 11
2016 7
2017 12
2018 12
2019 11
2020 14
2021 19
2022 19
2023 8
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

154 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G; KEYNOTE-042 Investigators. Mok TSK, et al. Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7. Epub 2019 Apr 4. Lancet. 2019. PMID: 30955977 Clinical Trial.
Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer.
Ding Z, Li Q, Zhang R, Xie L, Shu Y, Gao S, Wang P, Su X, Qin Y, Wang Y, Fang J, Zhu Z, Xia X, Wei G, Wang H, Qian H, Guo X, Gao Z, Wang Y, Wei Y, Xu Q, Xu H, Yang L. Ding Z, et al. Signal Transduct Target Ther. 2021 Jan 20;6(1):26. doi: 10.1038/s41392-020-00448-5. Signal Transduct Target Ther. 2021. PMID: 33473101 Free PMC article. Clinical Trial.
Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer.
Lu Y, Xue J, Deng T, Zhou X, Yu K, Deng L, Huang M, Yi X, Liang M, Wang Y, Shen H, Tong R, Wang W, Li L, Song J, Li J, Su X, Ding Z, Gong Y, Zhu J, Wang Y, Zou B, Zhang Y, Li Y, Zhou L, Liu Y, Yu M, Wang Y, Zhang X, Yin L, Xia X, Zeng Y, Zhou Q, Ying B, Chen C, Wei Y, Li W, Mok T. Lu Y, et al. Among authors: ding z. Nat Med. 2020 May;26(5):732-740. doi: 10.1038/s41591-020-0840-5. Epub 2020 Apr 27. Nat Med. 2020. PMID: 32341578 Clinical Trial.
Editorial: The Clinical Application of Neoantigens.
Zhou JG, Ding Z, Shi H, Cheng M. Zhou JG, et al. Among authors: ding z. Front Immunol. 2022 Mar 3;13:842633. doi: 10.3389/fimmu.2022.842633. eCollection 2022. Front Immunol. 2022. PMID: 35309343 Free PMC article. No abstract available.
The Ways of Isolating Neoantigen-Specific T Cells.
Li Q, Ding ZY. Li Q, et al. Front Oncol. 2020 Aug 11;10:1347. doi: 10.3389/fonc.2020.01347. eCollection 2020. Front Oncol. 2020. PMID: 32850430 Free PMC article. Review.
PD-1 Inhibitors in the Advanced Esophageal Cancer.
Hong Y, Ding ZY. Hong Y, et al. Front Pharmacol. 2019 Nov 29;10:1418. doi: 10.3389/fphar.2019.01418. eCollection 2019. Front Pharmacol. 2019. PMID: 31920637 Free PMC article. Review.
154 results